

# Phase II trial of high-dose, intermittent calcitriol (1,25 d dexamethasone in androgen-independent prostate cancer

Cancer

106, 2136-2142

DOI: [10.1002/cncr.21890](https://doi.org/10.1002/cncr.21890)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 97-104.	1.1	7
2	Antitumor Effects of Two Less-Calcemic Vitamin D Analogs (Paricalcitol and QW-1624F<sub>2</sub>-2) in Squamous Cell Carcinoma Cells. <i>Oncology</i> , 2006, 70, 483-492.	0.9	19
3	The vitamin D receptor as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 735-748.	1.5	66
4	The Roles of Vitamin E and Its Analogues in Prostate Cancer. <i>Vitamins and Hormones</i> , 2007, 76, 493-518.	0.7	8
5	Vitamin D status and cancer: new insights. <i>Current Opinion in Internal Medicine</i> , 2007, 6, 125-130.	1.5	31
7	Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 189-195.	1.0	22
8	Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 105, 140-149.	1.2	15
9	Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti-Inflammatory Activity. <i>Journal of Bone and Mineral Research</i> , 2007, 22, V74-V80.	3.1	56
10	Calcitriol Is a Potent Inhibitor of Retinal Neovascularization. , 2007, 48, 2327.		130
11	S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. <i>Prostate</i> , 2007, 67, 1498-1506.	1.2	12
12	Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. <i>Nature Reviews Cancer</i> , 2007, 7, 684-700.	12.8	1,215
13	Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 581-587.	1.1	42
16	The vitamin D receptor in cancer. <i>Proceedings of the Nutrition Society</i> , 2008, 67, 115-127.	0.4	124
17	Synergistic Antileukemic Activity of Carnosic Acid-Rich Rosemary Extract and the 19-nor Gemini Vitamin D Analogue in a Mouse Model of Systemic Acute Myeloid Leukemia. <i>Oncology</i> , 2008, 75, 203-214.	0.9	55
18	Vitamin D, vitamin D analogs (deltanoids) and prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 803-813.	1.3	0
19	Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice. <i>Endocrine Reviews</i> , 2008, 29, 726-776.	8.9	1,461
20	Shedding Light on Colorectal Cancer Prognosis: Vitamin D and Beyond. <i>Journal of Clinical Oncology</i> , 2008, 26, 2937-2939.	0.8	9
21	Clinical endpoints for drug development in prostate cancer. <i>Current Opinion in Urology</i> , 2008, 18, 303-308.	0.9	15

#	ARTICLE	IF	CITATIONS
22	Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. <i>Journal of Developmental and Physical Disabilities</i> , 2010, 33, 475-488.	3.6	178
23	Vitamin D deficiency and insufficiency among patients with prostate cancer. <i>BJU International</i> , 2009, 104, 909-914.	1.3	43
24	The promiscuous receptor. <i>BJU International</i> , 2009, 104, 1204-1207.	1.3	6
25	Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy. <i>Annals of Epidemiology</i> , 2009, 19, 96-102.	0.9	49
26	Differentiation therapy of leukemia: 3 decades of development. <i>Blood</i> , 2009, 113, 3655-3665.	0.6	295
27	The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. <i>Osteoporosis International</i> , 2010, 21, 1133-1149.	1.3	32
28	Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. <i>Cancer</i> , 2010, 116, 2132-2139.	2.0	41
29	The beneficial role of vitamin D and its analogs in cancer treatment and prevention. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 192-201.	2.0	28
30	p73 is essential for vitamin D-mediated osteoblastic differentiation. <i>Cell Death and Differentiation</i> , 2010, 17, 398-407.	5.0	29
31	Vitamin D, disease and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 941-955.	21.5	378
32	Prevalence of Overactive Bladder, its Under-Diagnosis, and Risk Factors in a Male Urologic Veterans Population. <i>International Journal of Medical Sciences</i> , 2010, 7, 391-394.	1.1	23
33	Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. <i>Endocrine-Related Cancer</i> , 2010, 17, R19-R38.	1.6	117
35	CYP24A1 Inhibition Enhances the Antitumor Activity of Calcitriol. <i>Endocrinology</i> , 2010, 151, 4301-4312.	1.4	77
36	The Vitamin D Receptor (NR1H1). , 2010, , 203-236.		0
37	Epigenetic silencing of CYP24 in the tumor microenvironment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 121, 338-342.	1.2	25
38	Glucocorticoid regulation of the vitamin D receptor. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 121, 372-375.	1.2	39
39	A Vitamin D Receptor-Alkylating Derivative of 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Inhibits Growth of Human Kidney Cancer Cells and Suppresses Tumor Growth. <i>Cancer Prevention Research</i> , 2010, 3, 1596-1607.	0.7	21
40	Prostate Cancer and Vitamin D: What Does the Evidence Really Suggest?. <i>Urologic Clinics of North America</i> , 2011, 38, 333-342.	0.8	12

#	ARTICLE	IF	CITATIONS
41	Vitamin D in Oncology. <i>Research in Complementary Medicine</i> , 2011, 18, 2-2.	2.2	7
42	Vitamin D and cancer: Clinical aspects. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011, 25, 605-615.	2.2	36
43	Vitamin D and Prostate Cancer. , 2011, , 221-249.		1
44	Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D. <i>Annual Review of Pharmacology and Toxicology</i> , 2011, 51, 311-336.	4.2	408
45	Vitamin D metabolism and action in the prostate: Implications for health and disease. <i>Molecular and Cellular Endocrinology</i> , 2011, 347, 61-69.	1.6	46
46	Hormonally Active Vitamin D3 (1 $\alpha$ ,25-Dihydroxycholecalciferol) Triggers Autophagy in Human Macrophages That Inhibits HIV-1 Infection. <i>Journal of Biological Chemistry</i> , 2011, 286, 18890-18902.	1.6	137
47	1 $\alpha$ ,25-Dihydroxyvitamin D3-3 $\beta$ -bromoacetate, a potential cancer therapeutic agent: Synthesis and molecular mechanism of action. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2537-2540.	1.0	7
48	Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2191-2198.	0.8	215
49	Dexamethasone Enhances 1 $\alpha$ ,25-Dihydroxyvitamin D3 Effects by Increasing Vitamin D Receptor Transcription. <i>Journal of Biological Chemistry</i> , 2011, 286, 36228-36237.	1.6	57
50	Vitamin D and Prostate Cancer. , 2011, , 1675-1709.		3
51	Dual functions of autophagy in the response of breast tumor cells to radiation. <i>Autophagy</i> , 2012, 8, 739-753.	4.3	143
52	Natural compounds as anticancer agents: Experimental evidence. <i>World Journal of Experimental Medicine</i> , 2012, 2, 45.	0.9	66
53	Buthionine Sulfoximine and 1,25-Dihydroxyvitamin D Induce Apoptosis in Breast Cancer Cells via Induction of Reactive Oxygen Species. <i>Cancer Investigation</i> , 2012, 30, 560-570.	0.6	12
54	Vitamin D and Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 58.	1.5	129
55	Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E1131-E1139.	1.8	13
56	Vitamin D and corticosteroids in asthma: synergy, interaction and potential therapeutic effects. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 101-104.	1.0	20
57	Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review. <i>Cancers</i> , 2013, 5, 255-280.	1.7	13
58	Vitamin D: Are We Ready to Supplement for Breast Cancer Prevention and Treatment?. <i>ISRN Oncology</i> , 2013, 2013, 1-22.	2.1	19

#	ARTICLE	IF	CITATIONS
59	Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1498-1507.	1.8	81
60	Early Growth Inhibition Is Followed by Increased Metastatic Disease with Vitamin D (Calcitriol) Treatment in the TRAMP Model of Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e89555.	1.1	33
61	Systemic Therapy of Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 247-273.	0.1	0
62	Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D<sub>3</sub>-based therapies. <i>FASEB Journal</i> , 2014, 28, 364-372.	0.2	57
63	Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , .	0.1	5
64	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Endocrine</i> , 2015, 50, 12-26.	1.1	53
65	From food to clinical medicineâ€”nutraceuticals as clinical therapeutics for hematological malignancies. <i>Current Opinion in Food Science</i> , 2015, 4, 7-12.	4.1	4
66	Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions. <i>Journal of Cancer</i> , 2016, 7, 391-407.	1.2	29
67	The Use of 1 $\alpha$ ,25-Dihydroxyvitamin D3 as an Anticancer Agent. <i>International Journal of Molecular Sciences</i> , 2016, 17, 729.	1.8	25
68	Vitamin D and urological cancers. <i>Central European Journal of Urology</i> , 2016, 69, 139-47.	0.2	10
69	Vitamin D Signaling Modulators in Cancer Therapy. <i>Vitamins and Hormones</i> , 2016, 100, 433-472.	0.7	15
70	Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1345-1349.	0.8	40
71	Vitamin D in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 244.	0.8	59
72	CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2821-2830.	0.8	14
73	The Antitumor Effects of Vitamin D in Genitourinary Cancer. , 2018, , 821-836.		0
74	Calcitriol and cancer therapy: A missed opportunity. <i>Bone Reports</i> , 2018, 9, 110-119.	0.2	26
75	Without 1 $\alpha$ -hydroxylation, the gene expression profile of 25(OH)D3 treatment overlaps deeply with that of 1,25(OH)2D3 in prostate cancer cells. <i>Scientific Reports</i> , 2018, 8, 9024.	1.6	15
76	Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients. <i>Cancer Causes and Control</i> , 2019, 30, 207-214.	0.8	6

#	ARTICLE	IF	CITATIONS
77	Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 203-219.	5.7	85
78	The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Hormone and Metabolic Research</i> , 2019, 51, 11-21.	0.7	29
79	Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2334.	1.8	23
80	Safety and efficacy of high dose pulse calcitriol and docetaxel for androgen-independent prostate cancer. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0151.	0.0	1
81	The Role of Bone Microenvironment, Vitamin D and Calcium. <i>Recent Results in Cancer Research</i> , 2012, 192, 33-64.	1.8	12
82	Liposomal 1,25-dihydroxyvitamin D <sub>3</sub> -3Î²-bromoacetate is a Stronger Growth-inhibiting Agent than its un-encapsulated Counterpart in Prostate Cancer Cells. <i>Journal of Steroids &amp; Hormonal Science</i> , 2010, 01, .	0.1	4
84	Hormonotherapy of Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2009, , 299-320.	0.1	0
85	Calcitriol and Vitamin D Analogs. , 2010, , 287-302.		0
86	Vitamin D and Cancerâ€™A Review. <i>US Endocrinology</i> , 2013, 09, 44.	0.3	0
87	Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. <i>American Journal of Clinical and Experimental Urology</i> , 2016, 4, 17-27.	0.4	5
88	Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12741.	1.8	17
90	Advantages and drawbacks of dexamethasone in glioblastoma multiforme. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103625.	2.0	16
91	Vitamin D and Hypoxia: Points of Interplay in Cancer. <i>Cancers</i> , 2022, 14, 1791.	1.7	3
92	Dietary Intake and Genetic Background Influence Vitamin Needs during Pregnancy. <i>Healthcare (Switzerland)</i> , 2022, 10, 768.	1.0	0
93	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6039-6055.	2.9	3
94	Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 18064-18078.	4.0	12
96	Selected Vitamins. , 0, , 385-415.		0
97	The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. <i>Antioxidants</i> , 2022, 11, 1090.	2.2	12

#	ARTICLE	IF	CITATIONS
98	Vitamin D and genetic ancestry are associated with apoptosis rates in benign and malignant prostatic epithelium. Prostate, 2023, 83, 352-363.	1.2	0
99	African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1A. Cancer Research Communications, 2023, 3, 621-639.	0.7	4
100	Vitamin D and prostate cancer. , 2024, , 917-935.		0